Search

Displaying results 1251 - 1260 of 5449 in total
  1. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor.

    Products: ANPROTSOM ® 60 MG, XAFILRED 60 MG/VIAL
  2. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.

    Products: Skyrizi 75 mg solution for injection in pre-filled syringe, Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADET
  3. Drug

    Gallamine triethiodide

    go.drugbank.com/drugs/DB00483
    ApprovedWithdrawn

    It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)

  4. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male

    Products: PABPCIB® 75 MG CAPSULAS, REAMPLA 75 MG KAPSÜL, 7 KAPSÜL
  5. Drug

    Fosphenytoin

    go.drugbank.com/drugs/DB01320
    ApprovedInvestigational

    It works by slowing down impulses in the brain that cause seizures.

  6. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    It was withdrawn from the United States market in April 1994.

  7. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    It serves as a negative feedback mechanism in the coagulation cascade.

  8. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099 … This milestone made it the first drug specifically approved to treat the neurologic manifestations of Hunter syndrome [L56099].

    Synonyms: - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T
  9. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    It is a lipophilic technetium phosphine dioxo cation that was formulated into a freeze-dried kit which yields an injection.

  10. Drug

    Lolium perenne pollen

    go.drugbank.com/drugs/DB10389
    Approved

    Lolium perenne pollen is the pollen of the Lolium perenne plant. Lolium perenne pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872